DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML

A Dose-finding Phase I/II Trial of Daunorubicin and Cytarabine Combined to Fractionated Mylotarg® as Re-induction Treatment in Patients With First Relapse of Acute Myeloid Leukemia

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02182596

Acronym

MYLOFRANCE2

Enrollment

Registered

2014-07-08

Start date

2006-06-30

Completion date

2011-01-31

Last updated

2014-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia

Keywords

Acute Myeloid Leukemia, First relapsing AML

Brief summary

For several years, the effective standard induction chemotherapy for AML has been limited to the association of anthracycline and aracytine. GO is the first effective targeted antibody used in leukemia patients. In a previous study, we showed efficacy and safety of fractionated doses of GO used as a single agent for treatment of adult AML patients in first relapse. In the present study the possibility of combining fractionated doses of GO to escalated doses of a 3+7 regimen old is studied in relapsed AML patients \> 50 and \<70 years.

Detailed description

Induction course are: GO 3mg/m2 on days 1, 4,7 + the three dose levels were as follows: level 1: DNR: 45 mg/m2 x 3 days + AraC: 100 mg/m2 x 7 days level 2: DNR: 60 mg/m2 x 3 days + AraC: 100 mg/m2 x 7 days level 3: DNR 60 mg/m2 x 3 days + AraC: 200 mg/m2 x 7 days. with 20 mg of methylprednisolone prior to each GO infusion. Consolidation course: patients in CR may receive 2 additional courses of consolidation chemotherapy with Amsacrine 90 mg/m2 daily for 3 days, and Ara-C (1g/m2/12 hours x 3 days) + GO 3 mg/m2 on day 1. Treatment with HSCT is offered at the discretion of the physician in charge of the patient. A delay between last infusion of GO and HSCT above 3 months is recommended

Interventions

DRUGMylotarg

Dose level study

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

50 Years to 70 Years

Healthy volunteers

Inclusion criteria

Patients with a morphologically proven diagnosis of CD33-positive AML and : 1. Age ≥ 50 years and ≤ 70 years. 2. First relapsing AML with a duration of first CR ≥ 3 and ≤18 months 3. ECOG performance status 0 to 3 4. Negative serology HIV, HBV and HBC (except post vaccination) 5. Serum creatinine ≤ 2N; AST and ALT ≤ 2N; total bilirubin ≤ 2N 6. Cardiac function determined by radionuclide or echography within normal limits. 7. Negative serum pregnancy test within one week before treatment for women of child bearing potential 8. Signed informed consent.

Exclusion criteria

1. M3-AML 2. AML following diagnosed myelodysplastic syndrome or myeloproliferation 3. Known central nervous system involvement with AML 4. Prior treatment with HSCT. 5. Previous treatment with Anti CD33 antibodies 6. Uncontrolled infection 7. Other active malignancy

Design outcomes

Primary

Measure	Time frame
Dose-limiting toxicity (DLT) defined by the occurrence of any G3 or G4 non reversible toxicity at day 45 excluding myelosuppression or infection due to neutropenia, and response defined by complete remission at day 45	Day 45 post first dose of treatment

Secondary

Measure	Time frame
Secondary endpoint: Duration of second remission in AML patients treated for relapse with chemotherapy + Mylotarg as re-induction and consolidation.	At two years

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026